1-11 of 11
Authors: W Kantasiripitak
Journal Article
P0869 Model-informed dosage de-escalation of infliximab in patients with inflammatory bowel diseases
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i1652–i1653, https://doi.org/10.1093/ecco-jcc/jjae190.1043
Published: 22 January 2025
Journal Article
OP12 Therapeutic antibody clearance better predicts endoscopic outcomes than trough concentrations in patients with Crohn’s disease
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i24–i26, https://doi.org/10.1093/ecco-jcc/jjae190.0012
Published: 22 January 2025
Journal Article
P531 A model-based tool for guiding infliximab induction dosing to maximise long-term deep remission in children with inflammatory bowel diseases
Journal of Crohn's and Colitis, Volume 17, Issue Supplement_1, February 2023, Pages i659–i661, https://doi.org/10.1093/ecco-jcc/jjac190.0661
Published: 30 January 2023
Journal Article
P701 A time-to-event model relating infliximab trough concentrations to the risk of relapse after extending the infusion interval
Journal of Crohn's and Colitis, Volume 17, Issue Supplement_1, February 2023, Pages i833–i834, https://doi.org/10.1093/ecco-jcc/jjac190.0831
Published: 30 January 2023
Journal Article
P333 Precise and unbiased infliximab dosing in patients with inflammatory bowel diseases using a multi-model averaging approach
Journal of Crohn's and Colitis, Volume 16, Issue Supplement_1, January 2022, Pages i350–i351, https://doi.org/10.1093/ecco-jcc/jjab232.460
Published: 21 January 2022
Journal Article
DOP89 Infliximab and ustekinumab clearance during induction predicts post-induction endoscopic outcomes in patients with Crohn’s Disease
Journal of Crohn's and Colitis, Volume 16, Issue Supplement_1, January 2022, Pages i131–i132, https://doi.org/10.1093/ecco-jcc/jjab232.128
Published: 21 January 2022
Journal Article
P533 Predictors of sustained remission after infliximab de-escalation in patients with inflammatory bowel diseases
Journal of Crohn's and Colitis, Volume 16, Issue Supplement_1, January 2022, Pages i485–i486, https://doi.org/10.1093/ecco-jcc/jjab232.660
Published: 21 January 2022
Journal Article
P497 The value of endoscopic healing index monitoring for guiding infliximab dosing in patients with Crohn’s disease
Journal of Crohn's and Colitis, Volume 15, Issue Supplement_1, May 2021, Pages S481–S483, https://doi.org/10.1093/ecco-jcc/jjab076.620
Published: 27 May 2021
Journal Article
P304 Rational infliximab induction dosing to achieve long-term deep remission in children with Inflammatory Bowel Diseases
Journal of Crohn's and Colitis, Volume 15, Issue Supplement_1, May 2021, Pages S332–S333, https://doi.org/10.1093/ecco-jcc/jjab076.428
Published: 27 May 2021
Journal Article
P542 The effect of age on infliximab pharmacokinetics in patients with inflammatory bowel disease
Journal of Crohn's and Colitis, Volume 14, Issue Supplement_1, January 2020, Pages S462–S463, https://doi.org/10.1093/ecco-jcc/jjz203.670
Published: 15 January 2020
Journal Article
P589 A population pharmacokinetic model to improve mucosal healing upon golimumab induction therapy in patients with ulcerative colitis Get access
Journal of Crohn's and Colitis, Volume 13, Issue Supplement_1, March 2019, Pages S409–S410, https://doi.org/10.1093/ecco-jcc/jjy222.713
Published: 25 January 2019
